Natera to Showcase Organ Health Leadership at American Transplant Congress
Natera, Inc. will present at the American Transplant Congress (ATC) with 21 presentations, including seven oral presentations, focusing on the Prospera test and its role in risk assessment and graft monitoring for various organ transplants.
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transp